ITM_Logo_Claim_RGB_high-res.png
ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network
September 08, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany, and Grand Rapids, MI, U.S., September 08, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and BAMF (Bold Advanced Medical...
22157.jpg
Global Genomics Partnering Deal Terms and Agreements Report/Directory 2022: Access to 900+ Deals Entered into by the World's Leading Healthcare Companies
September 05, 2022 06:58 ET | Research and Markets
Dublin, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Genomics Partnering Terms and Agreements 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.Access to 900+ Genomics...
ITM_Logo_Claim_RGB_high-res.png
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
August 18, 2022 05:18 ET | ITM Isotope Technologies Munich SE
• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
Theranostics in the fight against cancer
April 26, 2022 07:39 ET | University of the Free state
Bloemfontein, April 26, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or...
20170406 Telix Logo.png
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
August 17, 2021 21:26 ET | Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
20170406 Telix Logo.png
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
August 16, 2021 20:03 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has extended its previously...
22157.jpg
Global Somatic Genetic Testing Market Report 2021: Market to Reach $16.79 Billion by 2030
March 29, 2021 05:08 ET | Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Global Somatic Genetic Testing Market: Focus on Product Type, Sample, Technology, Applications, End Users, Country Data (15 Countries), and...
22157.jpg
Global Genomics Partnering Terms and Agreements Analysis Report 2020
February 11, 2021 06:28 ET | Research and Markets
Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Global Genomics Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering. The Global Genomics...
22157.jpg
Global Theranostics Markets Report 2020: Oncology Segment Market for Theranostics Should Grow from $73.1 Billion in 2020 to $119.7 Billion by 2025
October 26, 2020 07:23 ET | Research and Markets
Dublin, Oct. 26, 2020 (GLOBE NEWSWIRE) -- The "Theranostics: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for theranostics should grow from $80.4...
20170406 Telix Logo.png
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
August 17, 2020 20:00 ET | Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...